Omicron Variant of SARS-CoV-2 and Its Potential Impact on Dental Practice

REN Biao, LIAO Bin-you, WANG Jian-nan, PENG Xian, ZHOU Xue-dong

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been raging across the world for over two years, but the daily reported numbers of new infections and deaths are still increasing. The newly identified Omicron variant has significant changes in its transmissibility and pathogenicity due to the multiple mutations in the spike protein, posing new challenges to the global public health. World Health Organization has categorized Omicron as a variant of concern (VOC). The spread of SARS-CoV-2 and its variants has caused disruptions to the dental practice worldwide. During the course of diagnosis and treatment of dental care, face-to-face communication at close quarters, droplets, aerosols, and exposure to saliva and blood increase the risks of SARS-CoV-2 transmission. The emergence of new variants, especially the Omicron variant, has formed new challenges to dental healthcare provision. In addition, oral tissues, including the tongue and oral mucosa, can overexpress the angiotensin converting enzyme 2 (ACE2), which is also the binding receptors of SARS-CoV-2. As a result, the oral cavity is one of the target sites of SARS-CoV-2 infection. SARS-CoV-2 infection in oral cavity may cause different oral complications, such as loss of taste. However, there are few reports about Omicron and the other variants of SARS-CoV-2 and their impacts on dental healthcare provision. Herein we made an overview of the Omicron variant and its characteristics, including its pathogenicity and immune evasion, and its potential impact on dental practice. We also proposed some control measures with the aim of reducing the possible transmission of SARS-CoV-2 and its variants during dental care.

 

Keywords: COVID-19, SARS-CoV-2 variants, Omicron, Dental practice, Control measures

 

Full Text:

PDF


References


WHO. Weekly epidemiological update on COVID-19. (2022-01- 06)[2022-01-12]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

WU Z， HARRICH D， LI Z， et al. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV， MERS-CoV and 2009 H1N1 pandemic influenza virus. Rev Med Virol， 2021， 31(2): e2171[2022-01-22]. https://doi.org/10.1002/rmv.2171.

CUI J， LI F， SHI Z L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol，2019，17(3): 181–192.

ZHOU P， YANG X L， WANG X G， et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature， 2020，579(7798): 270–273.

SHAKAIB B， ZOHRA T， IKRAM A， et al. A comprehensive review on clinical and mechanistic pathophysiological aspects of COVID-19 Malady: How far have we come? Virol J，2021，18(1): 120.

AMORIM D S J， NORMANDO A， CARVALHO D S R， et al. Oral manifestations in patients with COVID-19: A living systematic review. J Dent Res，2021，100(2): 141–154.

ZHU F， ZHONG Y， JI H， et al. ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium. J Anat，2022，240(2): 398–409. ZHOU X， DONG J， GUO Q， et al. The oral complications of COVID-19. Front Mol Biosci， 2022， 8: 803785[2022-01-22]. https://doi.org/10. 3389/fmolb.2021.803785.

WHO. Tracking SARS-CoV-2 variants. (2021-12-06)[2021-12-13]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.

KHARE S E A. GISAID’s role in pandemic response. China CDC Wkly， 2021，3(49): 1049–1051.

WANG Q， ZHANG Y， WU L， et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell，2020，181(4): 894–904.

LAN J， GE J， YU J， et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature，2020，581(7807): 215–220.

SONG Y， MASAKI F. Preparation for the challenge of heavily mutated Omicron variant. Clin Transl Med， 2021， 11(12): e679[2022-01-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666579/. doi: 10.1002/ctm2.679.

CALLAWAY E. Heavily mutated Omicron variant puts scientists on alert. Nature，2021，600(7887): 21.

FANG F F， SHI P Y. Omicron: A drug developer’s perspective. Emerg Microbes Infect，2022，11(1): 208–211.

POUDEL S， ISHAK A， PEREZ-FERNANDEZ J， et al. Highly mutated omicron variant sparks significant concern among global experts—What is known so far? Travel Med Infect Dis， 2022， 45: 102234[2022-01-22]. https://doi.org/10.1016/j.tmaid.2021.102234.

FRAMPTON D， RAMPLING T， CROSS A， et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: A whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis，2021，21(9): 1246–1256.

HOFFMANN M， KLEINE-WEBER H， PÖHLMANN S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell，2020，78(4): 779–784.

PEACOCK T P， GOLDHILL D H， ZHOU J， et al. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. bioRxiv， 2020: 2020−2029[2022-01-22]. https://www.biorxiv.org/content/10.1101/2020. 09.30.318311v1.abstract.

GARCIA-BELTRAN W F， LAM E C， ST D K， et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell，2021，184(9): 2372–2383.

KARIM S， KARIM Q A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet，2021，398(10317): 2126–2128.

LAUER S A， GRANTZ K H， BI Q， et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med，2020，172(9): 577–582.

CDC COVID-19 Response Team. SARS-CoV-2 B. 1. 1.529 (Omicron) variant—United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep，2021，70(50): 1731–1734.

HOMMA Y， KATSUTA T， OKA H， et al. The incubation period of the SARS-CoV-2 B1.1. 7 variant is shorter than that of other strains. J Infect， 2021， 83(2): e15−e17[2022-01-22]. https://doi.org/10.1016/j.jinf.2021.06. 011.

SNELL L B， AWAN A R， CHARALAMPOUS T， et al. SARS-CoV-2 variants with shortened incubation periods necessitate new definitions for nosocomial acquisition. J Infect，2022，84(2): 248–288.

KUPFERSCHMIDT K， VOGEL G. Omicron threat remains fuzzy as cases explode. Science，2022，375(6576): 9–10.

IACOBUCCI G. Covid-19: Runny nose， headache， and fatigue are commonest symptoms of omicron， early data show. BMJ， 2021， 375: n3103[2022-01-22]. https://doi.org/10.1136/bmj.n3103.

HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung. Li Ka Shing Faculty of Medicine， The University of Hong Kong. (2021-12-15)[2022-01-12]. https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection.

GRAHAM F. Daily briefing: Omicron struggles to infect the lungs. Nature， 2022[2022-01-22]. https://www.nature.com/articles/d41586-022-00039-0. doi: 10.1038/d41586-022-00039-0.

COWPER A. Omicron: Who needs action when you’ve got Plan B? BMJ， 2022， 376: o15[2022-01-22]. https://doi.org/10.1136/bmj.o15. KOZLOV M. Omicron’s feeble attack on the lungs could make it less dangerous. Nature，2022，601(7892): 177.

DIAMOND M， HALFMANN P， MAEMURA T， et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq， 2021: rs.3.rs−1211792[2022-01-22]. https://www. researchsquare.com/article/rs-1211792/v1. doi: 10.21203/rs.3.rs-1211792/v1.


Refbacks

  • There are currently no refbacks.